drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Fourth-generation autologous gene-modified T cells expressing chimeric antigen receptors that co-target BCMA and CD19; administered as a single intravenous infusion (0.5–3 × 10^6 cells/kg) following lymphodepletion to deplete B-lineage cells in refractory autoimmune diseases.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous, gene‑modified T cells engineered with chimeric antigen receptors that co-target CD19 on B cells and BCMA on plasmablasts/plasma cells. Antigen engagement triggers CAR signaling to activate T‑cell cytotoxicity and cytokine release, leading to depletion of B‑lineage cells and reduction of autoreactive B cells and autoantibody‑producing plasma cells.
drug_name
SCAR02 (anti-BCMA/CD19 CAR-T cells)
nct_id_drug_ref
NCT06503224